Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 3.95% | -7.89% | -154.00% | 7.27% | -21.07% |
| Total Depreciation and Amortization | -342.58% | 2.35% | -15.01% | -78.48% | -46.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.44% | 8.84% | -0.61% | -90.54% | -39.87% |
| Change in Net Operating Assets | 80.46% | 788.70% | 97.39% | -173.27% | 792.98% |
| Cash from Operations | 15.15% | 32.31% | 19.39% | -93.22% | -35.77% |
| Capital Expenditure | -127.83% | -87.81% | 18.19% | 22.83% | 53.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 135.51% | -5.28% | -40.57% | -401.55% | 161.35% |
| Cash from Investing | 135.75% | -7.19% | -41.35% | -388.80% | 157.27% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -11.69% | 138.20% | -25.09% | 31,089.21% | -98.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -188.59% | -844.74% | -25.09% | 31,089.21% | -98.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 503.37% | -0.51% | -77.93% | 55.62% | -121.03% |
